Liver Cirrhosis: Pathophysiology, Diagnosis, and Management
DOI:
10.29303/jbt.v23i1.5763Published:
2023-12-16Downloads
Abstract
Liver disease is still a concern in world health and liver cirrhosis is the eleventh leading cause of death in the world. Cirrhosis caused 1.32 million deaths in 2017. Liver cirrhosis is a fibrosis or nodule formation in the liver. The study was conducted on databases, such as PubMed, google scholar and gray literature. With inclusion criteria, that are free full text publications published in 2015-2022 and having relevant discussions. Fibrosis in cirrhosis of liver begins with the activation of Stellate and Kupffer cells, damaged hepatocytes and activated platelets are also invoved. Inflammatory cells will appear as a result of the damage and cause fibrosis due to the secretion of cytokines. In addition, there are pathological features, namely nodule regeneration and loss of normal lobular architecture within the nodule. The patient's diagnosis start from anamnesis to gather information related to risk factors, physical examination, laboratory tests, imaging, liver biopsy if necessary. Management can be carried out according from etiology of the cause of liver cirrhosis. Complications of liver cirrhosis are portal hypertension, ascites, hepatic encephalopathy, hepatocellular carcinoma, hyponatremia, and acute kidney injury. Liver cirrhosis is a liver fibrosis caused by Stellate, Kupffer cells, damaged hepatocytes, and activated platelets. Inflammatory cells cause fibrosis, leading to regenerating nodules and decreased blood flow. Diagnosis involves anamnesis, physical examination, laboratory tests, imaging, and liver biopsy if needed. Treatment is based on the etiology of liver cirrhosis, with complications including portal hypertension, ascites, and hepatic encephalopathy.
Keywords:
Diagnosis, liver cirrhosis, management, pathophysiology.References
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., O'Brien, A. J., & Verma, S. (2021). Guidelines on the management of ascites in cirrhosis. Gut, 70(1), 9–29. DOI: https://doi.org/10.1136/gutjnl-2020-321790.
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of hepatology, 70(1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014
CDC. Chronic Liver Disease and Cirrhosis.Center for Disease Control and Prevention, https://www.cdc.gov/nchs/fastats/liver-disease.htm (2018, accessed 25 August 2022).
Eryta E, Saputra D, Siswoyo DV. (2021). Cirrhosis of Hepatis & Pulmonary Tuberculosis: A Case Report. Collaborative Medical Journal (CMJ) 4:21–25. DOI: https://doi.org/10.36341/cmj.v4i1.2163
Geong, G. Y., Kang, S. H., & Lee, C. M. (2019). An updated review on the epidemiology, pathophysiology, etiology and diagnosis of liver cirrhosis. DOI: 10.20944/preprints201903.0128.v1.
Gupta S, & Walker S. (2021). Testing for cirrhosis.Aust Prescr, 44:197–199. DOI: https://doi.org/10.18773/austprescr.2021.053
Mamone, G., Cortis, K., Sarah, A., Caruso, S., & Miraglia, R. (2018). Hepatic morphology abnormalities: beyond cirrhosis. Abdominal radiology (New York), 43(7), 1612–1626. DOI: https://doi.org/10.1007/s00261-017-1351-9.
Mansour, D., & McPherson, S. (2018). Management of decompensated cirrhosis. Clinical medicine (London, England), 18(Suppl 2), s60–s65. https://doi.org/10.7861/clinmedicine.18-2-s60.
Procopet B, & Berzigotti A. (2017). Diagnosis of cirrhosis & portal hypertension: Imaging, non-invasive markers of fibrosis & liver biopsy. Gastroenterol Rep (Oxf), 5: 79–89.
Procopet, B., & Berzigotti, A. (2017). Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterology report, 5(2), 79-89. DOI: 10.1093/gastro/gox012
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018). Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix biology: journal of the International Society for Matrix Biology, 68-69, 435–451. DOI: https://doi.org/10.1016/j.matbio.2018.04.006.
Sharma A & Nagalli S. (2022). Chronic Liver Disease. Treasure Island (FL): StatPearls Publishing, URL: https://www.ncbi.nlm.nih.gov/books/NBK554597/ (2022, accessed 25 August 2022).
Sharma B & John S. (2021). Hepatic Cirrhosis. Treasure Island (FL): StatPearls Publishing. URL: https://www.ncbi.nlm.nih.gov/books/NBK482419/
Smith, A., Baumgartner, K., & Bositis, C. (2019). Cirrhosis: diagnosis and management. American family physician, 100(12), 759-770. URL: https://pubmed.ncbi.nlm.nih.gov/31845776/
Smith, A., Baumgartner, K., & Bositis, C. (2019). Cirrhosis: diagnosis and management. American family physician, 100(12), 759-770. URL: https://pubmed.ncbi.nlm.nih.gov/31845776/
Sun, M., & Kisseleva, T. (2015). Reversibility of liver fibrosis. Clinics and research in hepatology and gastroenterology, 39 Suppl 1(0 1), S60–S63. DOI: https://doi.org/10.1016/j.clinre.2015.06.015.
Sureka, B., Bansal, K., Patidar, Y., Rajesh, S., Mukund, A., & Arora, A. (2015). Neurologic Manifestations of Chronic Liver Disease and Liver Cirrhosis. Current problems in diagnostic radiology, 44(5), 449–461. DOI: https://doi.org/10.1067/j.cpradiol.2015.03.004.
Wilson, R., & Williams, D. M. (2022). Cirrhosis. The Medical clinics of North America, 106(3), 437–446. DOI: https://doi.org/10.1016/j.mcna.2021.12.001.
Xu JH, Yu YY, Xu XY. (2020). Management of chronic liver diseases and cirrhosis: current status and future directions. Chin Med J (English), 133:2647–2649 DOI: 10.1097/CM9.0000000000001084
Yong, B. J. C., & Vidor, M. (2022). Sirosis Hepatis-Reversibel atau Irreversibel?. Cermin Dunia Kedokteran, 49(1), 43-46. DOI: https://doi.org/10.55175/cdk.v49i1.188.
License
Copyright (c) 2023 Baiq Nadya Putri Maharani, Aulia Dwi Hendriani, Putu Wika Pramesti Iswari
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
